Plasticell Release: Additional Family Of CombiCult® Patents Granted In USA, Europe, Australia And Singapore

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Stevenage, UK, 18 November 2013. Plasticell, the biotechnology company developing regenerative drugs using high throughput stem cell technologies, has announced that a further family of patents, offering additional protection of its proprietary cell culture technology, Combinatorial Cell Culture™ (CombiCult®), have been granted by the US Patent Office, European Patent Office, Australian Patent Office and Intellectual Property Office of Singapore.

The newly granted patents cover the use of nanomaterial tags to track the cell culture history of cells grown on beads and exemplify use of the method to deduce optimal culture conditions for the differentiation of stem cells. ‘These patents provide a secondary layer of coverage for Plasticell’s platform technology and extend the lifespan of patent protection,’ said Dr Yen Choo, founder and Executive Chairman of Plasticell and inventor of the methods.

Combinatorial Cell Culture™ forms the basis of the company’s CombiCult® system for high throughput screening of stem cell differentiation protocols. CombiCult® allows researchers to rapidly identify and/or optimise novel protocols which are highly efficient and/or cost-effective, free of undesirable media components such as serum, and to replace growth factors with small molecules.

Plasticell forms collaborations with industry partners to use CombiCult® in the production of rare cell types for research or therapy applications.

About Plasticell Ltd

Plasticell specialises in using massively parallel screens to differentiate stem cells. The company’s award winning technology, Combinatorial Cell Culture™ (CombiCultTM), allows testing of cell culture variables in combination to discover optimal laboratory protocols for the differentiation of pluripotent or adult stem cells. Plasticell forms strategic alliances with industry partners to produce high value cell lines for drug discovery and cell therapy applications. For more information visit: www.plasticell.co.u

For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (O) 207 203 6740 or e-mail: t.jervis@defacto.com.

Help employers find you! Check out all the jobs and post your resume.

Back to news